Loading data for PALI — first visit, this takes a few seconds.

Preisalarm

Palisade Bio Inc. (PALI)

NasdaqCM: PALI · Echtzeitkurs · USD

2.12

+0.08 (3.92%)

Zum Schluss: Aug 19, 2026, 8:00 PM

2.13

-1.39%

Nachbörslich: 4:29 PM

3.92% (1D)

Keine Daten verfügbar

Geld	1.54
Marktkapitalisierung	376.42 Mio
Umsatz (TTM)	500K
Nettogewinn (TTM)	-31.94 Mio
Beta	1.54
EPS (ttm)	0.65
KGV (TTM)	3.32
Forward-KGV	-7.71
KBV (TTM)	3.08
KUV (TTM)	752.85
Earnings Date	n/a

Brief	2.68
Volumen	1,294,124
Ø Vol. (20D)	3,141,403
Eröffnung	2.10
Vortagesschluss	2.04
Tagesspanne	2.08 - 2.19
52-Wk Range	0.53 - 2.86
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research c...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Mar 30, 2007

Mitarbeiter 14

Börse NasdaqCM

Tickersymbol PALI

Website https://www.palisadebio.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Palisade Bio 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -16.78 Mio, ein Anstieg von 16.23 %.

Finanzberichte

Gewinnüberraschung

Palisade Bio hat die Quartalszahlen am Aug 10, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -0.05 verfehlt die Erwartungen um 0.00, mit 92.75% Wachstum im Jahresvergleich.

Nachrichten

vor 3 Wochen · Benzinga

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market. The company...

vor 1 Monat · Stocktwits

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?

Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.

vor 2 Monaten · Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

vor 3 Monaten · Motley Fool

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

vor 3 Monaten · Insider Monkey

Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M

Palisade Bio Inc. (NASDAQ:PALI) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, Palisade reported Q1 2026 earnings, recording a net increase in operating expenses to fund its cl...

Seite 1 von 2

Palisade Bio Inc. (PALI)